TP53 and cancer: For instance, the protein-ubiquitin ligase MDM2 which targets p53 for degradation is well-known to be a dependency in TP53 wild-type cancers, but inhibition of MDM2 is ineffective in cancers that already harbor loss of p53 function28,29,39.